Contact Us

Home

About us

Services

AI Excellence

case studies

publications

HEOR Certificationheor Certification

AI for Medical Writing

Contact

  • Strategizing Optimal Collection and Use of Real-World Data from Expanded Access Programs

    Strategizing Optimal Collection and Use of Real-World Data from Expanded Access Programs
    Strategizing Optimal Collection and Use of Real-World Data from Expanded Access Programs

    Expanded Access Programs (EAPs) are special programs designed to provide patients with serious or life-threatening conditions access to investigational treatments that have not yet been approved by regulatory authorities, offering them a chance to receive potentially beneficial therapies when no other options are available. EAPs not only offer a lifeline to patients but also present an exceptional opportunity to gather Real-World Data (RWD). By strategically harnessing data from EAPs, researchers and healthcare stakeholders can unravel a wealth of insights that contribute to evidence-based decision-making and drive improvements in patient care. However, the successful collection and strategic utilization of data from EAPs require careful planning, ethical considerations, and methodological rigor.[1,2]

    Ethical data collection from EAPs is paramount to their usage as RWD sources. The collection of patient data from EAP must prioritize patient privacy, informed consent, and data security. Striking a balance between patients’ urgent medical needs and their rights as research subjects is crucial.[3]

    A comprehensive data collection strategy begins by defining the specific data elements to be collected from EAP participants. This could include demographic information, disease characteristics, treatment regimens, adverse events, and patient-reported outcomes. Collaborating with healthcare professionals and patient advocates can help identify relevant data points contributing to a holistic understanding of treatment outcomes.[4]

    Establishing a robust data collection infrastructure is pivotal. Electronic health records, patient registries, and digital health platforms can facilitate seamless and standardized data collection. Integrating data collection into routine clinical workflows minimizes the burden on healthcare providers and ensures data accuracy.[4]

    Incorporating patient-reported outcomes (PROs) in the EAPs empowers patients to contribute their perspectives on treatment experiences and quality of life. Digital tools and mobile apps can streamline the collection of PROs, providing real-time insights into patient well-being. Additionally, maintaining data quality and reliability is paramount to drawing meaningful insights from EAPs. Implementing data validation protocols, standardized data entry procedures, and regular data audits mitigate the risk of inaccuracies and enhance the credibility of the collected data.[4]

    RWD from EAPs can also shed light on healthcare resource utilization by providing insights on hospitalization rates, length of stay, and use of medical services. By using this data, healthcare systems can make informed decisions about resource allocation and patient care planning.[3,4]

    Challenges in EAP data collection and utilization are not uncommon. One challenge is the potential for selection bias due to the non-randomized nature of EAPs. Patients with specific characteristics might be more likely to participate, introducing bias into the data. To mitigate this, advanced statistical techniques, such as propensity score matching, can be employed. Additionally, data completeness can be an issue due to variations in healthcare settings and patient engagement levels. Implementing data quality checks and incentives for data submission can encourage comprehensive data collection.[3,4]

    The optimal collection and use of RWD from EAPs hold immense potential to shape healthcare decisions, policy formulation, and patient care. Collaborative efforts among healthcare professionals, researchers, patient advocates, and regulatory bodies are essential to harness the full potential of RWD. As technology advances and data collection methodologies evolve, the seamless integration of EAP data into evidence-based medicine promises a brighter future for patients seeking hope beyond conventional treatment options. By navigating the ethical considerations, implementing robust data collection strategies, and leveraging advanced analytical techniques, stakeholders can unlock the power of RWD to improve patient outcomes and advance medical knowledge.

    Become A Certified HEOR Professional – Enrol yourself here!

    References

    1. Polak TB, Cucchi DG, Schelhaas J, Ahmed SS, Khoshnaw N, van Rosmalen J, Uyl-de Groot CA. Results from Expanded Access Programs: A Review of Academic Literature. Drugs. 2023 May 18:1-1.
    2. Polak TB, Cucchi DG, van Rosmalen J, Uyl-de Groot CA, Darrow JJ. Generating evidence from expanded access use of rare disease medicines: challenges and recommendations. Frontiers in Pharmacology. 2022:1917.
    3. Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals. BMJ Open. 2022 Jan 6;12(1):e052186.
    4. Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. Br J Clin Pharmacol. 2020 Sep;86(9):1819-1826.

    MarksMan Healthcare

    , , ,

  • Evaluating Medical Devices: How Do RCT Data and RWD Fit Together?

    Evaluating Medical Devices: How Do RCT Data and RWD Fit Together?
    The banner image talks about evaluation of medical devices using RCT and RWD

    Medical devices play a critical role in modern healthcare, aiding in diagnosing, treating, and managing various diseases and conditions. Before these devices are approved for widespread use, they undergo rigorous evaluation to ensure their safety and effectiveness. Two key sources of data used in the evaluation process are Randomized Control Trial (RCT) data and Real-World Data (RWD). While RCTs provide controlled and standardized evidence, RWD reflects the device’s performance in everyday clinical practice. Understanding how these two sources of data complement each other is essential for making informed decisions about medical device adoption and patient care.(1)

    RCTs are widely regarded as the gold standard for assessing the safety and efficacy of medical devices. These trials involve carefully designed studies where participants are randomly assigned to different treatment groups. This randomization minimizes bias and allows for the comparison of treatment outcomes. RCTs follow predefined protocols and often have strict inclusion and exclusion criteria, which helps ensure a homogeneous study population.(2,3)

    RCT data provides valuable insights into the specific device being evaluated. Researchers meticulously collect and analyze data, monitoring participant outcomes, adverse events, and treatment response. The controlled environment of RCTs allows for a detailed examination of the device’s performance, enabling researchers to draw reliable conclusions about its effectiveness. Furthermore, the blinding and randomization processes in RCTs help minimize confounding factors and enhance the internal validity of the findings.(3)

    While RCTs provide vital initial evidence, RWD offers a complementary perspective on medical device performance. RWD is collected from routine clinical practice and reflects the device’s use in diverse patient populations, various healthcare settings, and in the presence of coexisting conditions. This data is obtained from electronic health records, claims databases, registries, and other sources, providing information about a device’s long-term effectiveness and safety.(4)

    RWD captures the complexity of patient care and provides insights into how a device performs in everyday clinical practice. It helps identify potential issues that may not have emerged during the controlled setting of RCTs. RWD can uncover rare adverse events, treatment challenges in specific patient subgroups, and the durability of device efficacy over time. Additionally, it enables the evaluation of device performance in real-world settings, where factors such as operator experience and patient adherence come into play.(4,5)

    While RCTs and RWD have distinct strengths, combining these sources of information can enhance our understanding of medical device performance. RCT data establishes the initial evidence base and provides critical insights into the device’s efficacy under controlled conditions. This data is often used to support regulatory approval and guide initial clinical decisions.(4-6)

    RWD, on the other hand, supplements RCT findings by providing a broader view of device performance in diverse patient populations and real-world clinical settings. It can help identify potential risks or benefits that may not have been apparent during the controlled environment of an RCT. Moreover, RWD can inform post-market surveillance efforts, aiding in continuously monitoring device safety and effectiveness.(4)

    The integration of RCT data and RWD can help address limitations inherent in each dataset. For example, while RCTs may have limited sample sizes and shorter follow-up periods, RWD can provide insights into long-term outcomes and rare adverse events. Conversely, RWD may suffer from biases, such as confounding variables or incomplete documentation, which can be mitigated by the controlled design of RCTs.(2)

    Evaluating medical devices requires a comprehensive approach that combines the strengths of both RCT data and RWD. RCTs establish the initial evidence base, while RWD provides insights into the device’s performance in diverse patient populations and everyday clinical practice. The synergy between these two data sources is crucial for informed decision-making regarding medical device adoption, patient care, and post-market surveillance. By embracing a holistic approach to data evaluation, we can maximize the benefits and safety of medical devices, ultimately improving patient outcomes.

    Become a Certified HEOR Professional – Enrol yourself here!

    References:

    1. Ming J, He Y, Yang Y, et al. Health technology assessment of medical devices: current landscape, challenges, and a way forward. Cost Effectiveness and Resource Allocation. 2022 Dec;20(1):1-9.
    2. Tarricone R, Boscolo PR, Armeni P. What type of clinical evidence is needed to assess medical devices? Eur Respir Rev. 2016 Sep;25(141):259-65.
    3. Tarricone R, Callea G, Ogorevc M, Prevolnik Rupel V. Improving the methods for the economic evaluation of medical devices. Health Economics. 2017 Feb;26:70-92.
    4. U.S. Food and Drug Administration. FDA. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. 2023; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices.
    5. Dhruva SS, Ross JS, Desai NR. Real-world evidence: promise and peril for medical product evaluation. Pharmacy and Therapeutics. 2018 Aug;43(8):464.
    6. Valla V, Tzelepi K, Charitou P, et al. Use of Real-World Evidence for International Regulatory Decision Making in Medical Devices. International Journal of Digital Health. 2023 Jan 1;3(1):1.

    MarksMan Healthcare

    , , ,

  • External Control Arms (ECA): Optimizing Submissions to HTA Agencies

    External Control Arms (ECA): Optimizing Submissions to HTA Agencies
    External Control Arms (ECA): Optimizing Submissions to HTA Agencies

    In the realm of pharmaceutical development, the pursuit of safe and effective treatments is paramount. To achieve this, rigorous clinical trials are conducted to evaluate the efficacy and safety of new interventions. However, the traditional randomized controlled trial (RCT) framework, while invaluable, is not always feasible or ethical. In such cases, External Control Arms (ECAs) have emerged as a potential solution.(1)

    ECA refers to a trial design strategy where an experimental treatment arm is compared to a control group using external data rather than traditional randomization. This approach is particularly useful when randomization is impractical, such as in rare diseases or when the experimental treatment is intended for patients with no other viable options. ECAs utilize historical, observational, or real-world data to construct an appropriate control arm against which the experimental treatment can be evaluated. (2,3)

    Creating an ECA involves several steps. First, a suitable data source is identified, which could include medical registries, electronic health records, or administrative databases. The control group is then defined using patient-level data from the chosen source. Statistical methods, such as propensity score matching or weighting, are often employed to balance the characteristics of the treatment and control groups, reducing bias and ensuring comparability.(4)

    ECAs offer several advantages over traditional RCTs. They can expedite the evaluation process by providing more timely results, potentially accelerating patient access to promising therapies. ECAs can also be more cost-effective, as they utilize existing data rather than requiring the recruitment and monitoring of additional participants. Furthermore, they can fill the evidence gap in rare diseases, where conducting RCTs may be challenging due to limited patient populations. ECAs offer an opportunity to evaluate interventions in such cases, providing valuable insights for patients and healthcare providers.(1, 3)

    However, ECAs also have their limitations. As they rely on non-randomized data, there is an inherent risk of confounding and bias. While statistical methods can mitigate some of these concerns, residual confounding remains a potential issue. Additionally, the use of ECAs requires careful consideration and discussion with regulatory bodies, as there may be skepticism regarding the reliability and generalizability of the external data. Striking a balance between the benefits and limitations of ECAs is crucial to ensure their appropriate and ethical application.(2)

    Optimizing ECAs for submission to HTA agencies involves careful planning and execution. First and foremost, robust data sources with high-quality information are essential. This may involve collaborations with data custodians, healthcare institutions, or research networks to access relevant datasets. Additionally, comprehensive data analysis plans should be developed, specifying the statistical methods to be employed, addressing potential biases, and ensuring transparency in reporting results.(1, 2)

    Collaboration and engagement with HTA agencies throughout the ECA process is crucial. Early dialogue can help align expectations, address methodological concerns, and understand the specific requirements of the agency. Transparent reporting of data sources, study limitations, and potential biases is essential for successful submission. It is imperative to demonstrate the validity and reliability of the ECA results and their relevance to the target population.(5)

    In the current landscape, regulations and guidelines regarding ECAs for HTA submissions are still evolving. HTA agencies are increasingly recognizing the value of ECAs as an alternative to traditional RCTs, particularly in situations where randomization is not feasible. As the field progresses, it is expected that guidelines and frameworks will continue to be refined to ensure standardized and rigorous evaluation of ECAs.(2, 5)

    In conclusion, External Control Arms (ECAs) provide a valuable alternative to traditional randomized controlled trials, particularly in cases where randomization is not feasible or ethical. Their ability to expedite the evaluation process, fill evidence gaps in rare diseases, and potentially reduce costs make them an appealing option. However, careful consideration of potential biases and engagement with HTA agencies are crucial to ensure the appropriate use and optimization of ECAs for submissions. As the field continues to evolve, collaboration and transparent reporting will be key to harnessing the full potential of ECAs in advancing pharmaceutical research and development.

    Become A Certified HEOR Professional – Enrol yourself here!

    Reference

    1. Davi R, Mahendraratnam N, Chatterjee A, et al. Informing single-arm clinical trials with external controls. Nat Rev Drug Discov. 2020 Dec;19(12):821-822.
    2. Burcu M, Dreyer NA, Franklin JM, et al. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1228-1235.
    3. Ventz S, Lai A, Cloughesy TF, et al. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 Aug 15;25(16):4993-5001.
    4. Seeger JD, Davis KJ, Iannacone MR, et al. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1382-1392.
    5. Curtis LH, Sola-Morales O, Heidt J, et al. Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls. Clin Pharmacol Ther. 2023 Apr 20.

    MarksMan Healthcare

    , , ,